Xilio Therapeutics Inc
Change company Symbol lookup
Select an option...
XLO Xilio Therapeutics Inc
PHT Pioneer High Income Fund, Inc.
BTAL AGFiQ U.S. Market Neutral Anti-Beta Fund
BIGC Bigcommerce Holdings Inc
OP Oceanpal Inc
AMZN Amazon.com Inc
BHR Braemar Hotels & Resorts Inc
X United States Steel Corp
ELV Elevance Health Inc
SREA Sempra Energy
Go

Company profile

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.

Closing Price
$2.37
Day's Change
-0.04 (-1.66%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.40
Day's Low
2.37
Volume
(Light)
Volume:
22,184

10-day average volume:
131,628
22,184

Display:

Providers:

UpdateCancel
6 providers
August 09, 2022
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results

XTX101, tumor-selective anti-CTLA-4, has successfully reached dose levels exceeding the target dose with limited active (unmasked) molecule in the periphery in ongoing Phase 1 clinical trial XTX202, tumor-selective IL-2, advancing in...(Globe Newswire)

June 16, 2022
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President

EQNX::TICKER_START (NASDAQ:XLO), EQNX::TICKER_END Paul Clancy Elected as Chair of the Board of Directors Robert Ross, M.D., Appointed to Board of Directors Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.